Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
Emmanuelle Tavernier(Institute Cancer De La Loire Lucien Neuwirth), Xavier Thomas(Hôpital Lyon Sud), Françoise Huguet(Centre Hospitalier Universitaire de Toulouse), Agnès Buzyn(Hôpital Saint-Jacques), Véronique Lhéritier(Hospices Civils de Lyon), Pierre Fenaux(Saint Louis University Hospital), Claude Boucheix(Inserm), Olivier Tournilhac, Norbert Vey(Centre de Recherche en Cancérologie de Marseille), Aspasia Stamatoullas(European Union), Nathalie Fegueux(European Union), J Gäbert(Institut Paoli-Calmettes), K. F. Bradstock(Westmead Hospital), JM Boiron(Hôpital Cardiologique du Haut-Lévêque), Tibor Kovacsovics(Hôpital Edouard Herriot), Vernant Jp(Sorbonne Université), C Charrin(Hôpital Edouard Herriot), Oumédaly Reman(Centre Hospitalier Universitaire de Caen), André Delannoy(Hôpital Saint-Jacques), Hervé Dombret(University of London Institute in Paris)
Cited by 258
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k